The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion by 2030, according to new research.

Figures published by research firm Roots Analysis forecast the sector to grow at a compound annualised rate of 28% over the next nine years.

Roots’ analysis attributed this growth to CAR-T therapies’ ability to direct the human immune system to attack cancer cells, leading to prolonged remission periods.

“Several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status,” the company added.

The report noted that at least four CAR-T therapies have already been approved for use, with many more viable candidates currently under evaluation.

“The CAR-T cell therapy market is characterized by a healthy and growing pipeline,” the research noted.

“Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.”

Current generation CAR-T treatments remain costly

While CAR-T represents a breakthrough in the treatment of several B-cell cancer types, new research from Prime Therapeutics shows the current generation of treatments for B-cell lymphoma cost an average of US $700,000.

While the actual wholesale cost of the drugs used during this treatment only cost an average US $373,000, this amount swells by a further US $300,000 plus when factoring in post-treatment care.

In 12% of cases, the total cost of current generation B-cell lymphoma CAR-T and post-treatment care, including drugs and other costs, totalled US $1 million or more.

A handful of companies, including the Australian-listed Prescient Therapeutics (ASX: PTX), are now developing the next generation of these treatments with a view to making them safer and – notably – more affordable for patients.

To stay up-to-date on Prescient Therapeutics’ news and announcements, register your details at their investor centre.

Reach Markets have been engaged by PTX to help manage their investor communications.

Sources:

• Pharmacy Times, Study Finds Total Cost of Care for CAR-T, Post-Treatment Events Can Exceed $1 Million
• Prime Therapeutics, Prime Therapeutics’ study shows total cost of care for CAR-T plus post-treatment events can exceed $1 million
• Root Analysis, The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis
• Stockhead, Prescient gears up for growth with $6.5m raise as the race to cure cancer heats up